News
Dizal breaks new ground for EGFR drugs in lung cancer
Dizal's Zegfrovy has taken the oral EGFR inhibitor class into new territory, with a phase 3 win as a frontline treatment for a form of lung cancer.
Sunday 12 April 2026
